RÉSUMÉ
BACKGROUND AND AIMS: Laboratory studies on human adipose tissue and differentiated adipocytes indicate that natriuretic peptides (NPs) affect lipid metabolism and plasma cholesterol. Few previous clinical studies in non-elderly populations found associations between NPs in the physiological range and cholesterol. AIM: evaluate the association between NT-proBNP and lipid profile in very elderly hospitalized patients characterized by a wide range of NT-proBNP levels. METHODS AND RESULTS: Cross-sectional study on 288 very elderly patients hospitalized for medical conditions, in which increased NT-proBNP levels are very common. NT-proBNP, total cholesterol (TC), HDL cholesterol (HDLc) and triglycerides were collected just few days before discharge. Patients taking lipid-lowering drugs and patients with an admission diagnosis of acute heart failure were excluded. Calculated LDL-cholesterol (LDLc) was used for the analyses. Mean age: 87.7 ± 6.2 years; female prevalence (57.3%). Median NT-proBNP: 2949 (1005-7335) pg/ml; mean TC: 145.1 ± 40.3 mg/dl; mean HDLc: 38.4 ± 18.6 mg/dl; median triglycerides: 100 (75-129) mg/dl; mean LDLc: 84.0 ± 29.5 mg/dl. We found negative correlations between NT-proBNP and both TC and LDLc (Rho = -0.157; p = 0.008 and Rho = -0.166; p = 0.005, respectively), while no correlations emerged between NT-proBNP and HDLc (Rho = -0.065; p = 0.275) or triglycerides (Rho = -0.009; p = 0.874). These associations were confirmed considering NT-proBNP tertiles. The inverse association between NT-proBNP and LDLc was maintained even after adjusting for confounding factors. CONCLUSION: Our real-life clinical study supports the hypothesis that NPs play a role on cholesterol metabolism, given the association found between LDLc and NT-proBNP even in very elderly patients where NT-proBNP values are often in the pathological range.
Sujet(s)
Vieillissement/sang , Cholestérol LDL/sang , Peptide natriurétique cérébral/sang , Fragments peptidiques/sang , Facteurs âges , Sujet âgé de 80 ans ou plus , Marqueurs biologiques/sang , Études transversales , Femelle , Humains , Patients hospitalisés , Mâle , Admission du patientRÉSUMÉ
Cardiac natriuretic peptides (NP) are involved in cardiorenal regulation and in lipolysis. The NP activity is largely dependent on the ratio between the signaling receptor NPRA and the clearance receptor NPRC. Lipolysis increases when NPRC is reduced by starving or very-low-calorie diet. On the contrary, insulin is an antilipolytic hormone that increases sodium retention, suggesting a possible functional link with NP. We examined the insulin-mediated regulation of NP receptors in differentiated human adipocytes and tested the association of NP receptor expression in visceral adipose tissue (VAT) with metabolic profiles of patients undergoing renal surgery. Differentiated human adipocytes from VAT and Simpson-Golabi-Behmel Syndrome (SGBS) adipocyte cell line were treated with insulin in the presence of high-glucose or low-glucose media to study NP receptors and insulin/glucose-regulated pathways. Fasting blood samples and VAT samples were taken from patients on the day of renal surgery. We observed a potent insulin-mediated and glucose-dependent upregulation of NPRC, through the phosphatidylinositol 3-kinase pathway, associated with lower lipolysis in differentiated adipocytes. No effect was observed on NPRA. Low-glucose medium, used to simulate in vivo starving conditions, hampered the insulin effect on NPRC through modulation of insulin/glucose-regulated pathways, allowing atrial natriuretic peptide to induce lipolysis and thermogenic genes. An expression ratio in favor of NPRC in adipose tissue was associated with higher fasting insulinemia, HOMA-IR, and atherogenic lipid levels. Insulin/glucose-dependent NPRC induction in adipocytes might be a key factor linking hyperinsulinemia, metabolic syndrome, and higher blood pressure by reducing NP effects on adipocytes.
Sujet(s)
Adipocytes/métabolisme , Glucose/pharmacologie , Coeur/effets des médicaments et des substances chimiques , Hypoglycémiants/pharmacologie , Insuline/pharmacologie , Natriurèse/effets des médicaments et des substances chimiques , Peptides natriurétiques/métabolisme , Récepteur facteur natriurétique auriculaire/métabolisme , Adipocytes/effets des médicaments et des substances chimiques , Sujet âgé , Cellules cultivées , Femelle , Humains , Insuline/sang , Graisse intra-abdominale/cytologie , Graisse intra-abdominale/effets des médicaments et des substances chimiques , Graisse intra-abdominale/métabolisme , Lipides/sang , Mâle , Récepteur facteur natriurétique auriculaire/antagonistes et inhibiteurs , Récepteur facteur natriurétique auriculaire/effets des médicaments et des substances chimiques , Transduction du signal/effets des médicaments et des substances chimiques , Régulation positive/effets des médicaments et des substances chimiquesRÉSUMÉ
The catecholamines and the adrenergic receptors have been long known to be vital components in the regulation of fat cell metabolism. Whether in response to stress, cold temperature or diet, the ß-adrenergic receptors (ßARs) respond to epinephrine/norepinephrine to activate a signalling cascade that drives triglyceride hydrolysis to free fatty acids for use as fuel for skeletal and cardiac muscle work. The ßARs also are well-established activators of brown fat for the conversion of substrate energy to generate heat from the oxidation of glucose and fatty acids. Long thought to be irrelevant to the biology of adult humans, the realization that there is indeed functional brown fat in humans has now created great interest and enthusiasm over the possibility that recruiting brown fat to target obesity and metabolic disease could represent a viable therapeutic option. Coupled with newer evidence that various stimuli independent of the ßARs may also be able to increase active brown adipocytes, including the cardiac natriuretic peptides, it is an exciting time to be working in this area. This review will focus on the catecholamines and natriuretic peptides as cooperative actors in promoting fat metabolism, and will consider areas in need of further research.
RÉSUMÉ
BACKGROUND AND AIMS: Rare (611C) and common (1062V) variants of the Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) display reduced activation of Wnt/ß-catenin signaling. The rare gene variant was associated with hypertension, metabolic abnormalities, and early coronary artery disease. We investigated whether the common 1062V LRP6 variant was related to carotid artery atherosclerosis (CAA) in hypertensive patients. METHODS AND RESULTS: Retrospective study of 334 hypertensive patients (<65 years old) who underwent carotid artery ultrasonography. Hypertension, type 2 diabetes, dyslipidemia, glomerular filtration rate, and smoking habit were evaluated. CAA was defined by the presence of atherosclerotic plaques (focal intima-media thickness ≥ 1.3 mm). Logistic regression models were used to estimate the independent effect of 1062V allele. The relationship between LRP6 genotypes and LRP6 gene expression in carotid plaques was also investigated. No difference was observed between genotypes in clinical variables except for a slightly higher fasting glucose in 1062V carriers. The 1062V LRP6 variant was an independent risk factor for CAA in both unadjusted (OR 2.08, 95%CI 1.27-3.41, p=0.003) and adjusted models (OR 1.92, 95%CI 1.09-3.39, p=0.02). LRP6 was expressed in carotid atherosclerotic plaques at significantly lower levels (p=0.015) in 1062V carriers. CONCLUSION: Beside the role of established risk factors, 1062V variant of LRP6 and CAA are strongly associated in hypertensive patients, making LRP6 a novel relevant candidate gene for atherosclerosis in the presence of hypertension.
Sujet(s)
Artériopathies carotidiennes/génétique , Hypertension artérielle/génétique , Protéines apparentées au récepteur LDL/génétique , Protéines apparentées au récepteur LDL/métabolisme , Adulte , Artériopathies carotidiennes/métabolisme , Femelle , Expression des gènes , Humains , Hypertension artérielle/métabolisme , Modèles logistiques , Protéine-6 apparentée au récepteur des LDL , Mâle , Adulte d'âge moyen , Plaque d'athérosclérose/métabolisme , Études rétrospectives , Facteurs de risque , Transduction du signal , Protéines de type Wingless/génétique , Protéines de type Wingless/métabolisme , bêta-Caténine/génétique , bêta-Caténine/métabolismeRÉSUMÉ
Human angiotensinogen (AGT) gene promoter polymorphisms (G-217A; A-20C; G-6A) influence AGT transcription in vitro and have been implicated in the genetics of essential hypertension. We analysed the association among AGT promoter variants and AGT mRNA levels in human kidney and visceral adipose tissue (VAT) in vivo. Samples of kidney and VAT were obtained from 35 consecutive patients undergoing renal surgery. The AGT gene promoter of each patient was sequenced to identify variants. AGT gene expression was studied by real-time PCR TaqMan assay. Clinical data obtained before surgery were also considered in the statistical analysis. Two new polymorphisms at -175 and at -163 were identified. Although AGT expression was significantly higher in VAT than in the kidney, when both variants were present together AGT expression in VAT was about fivefold lower (P=0.033) than in the wild haplotype. This lower AGT expression in VAT suggests that the proximity and linkage of -175A and -163A variants might destabilize the binding of specific transcription factors to an acute-phase responsive element 3. Among the known AGT promoter variants, only -20C SNP has an important effect on tissue-specific differential AGT expression in the human tissues studied, inducing a 3.8-fold increase in AGT mRNA localized only in the kidney medulla (P=0.038). The other known polymorphisms (G-6A; G-217A) were not associated with different levels of AGT expression. Our results support the hypothesis that some human AGT promoter variants influence transcriptional activity in a tissue-specific way in humans.
Sujet(s)
Angiotensinogène/génétique , Hypertension rénale/génétique , Graisse intra-abdominale/physiologie , Cortex rénal/physiologie , Médulla rénale/physiologie , Régions promotrices (génétique)/génétique , Sujet âgé , Séquence nucléotidique , Femelle , Expression des gènes , Génotype , Humains , Mâle , Adulte d'âge moyen , Données de séquences moléculaires , Obésité/génétique , Spécificité d'organe , Polymorphisme de nucléotide simple , ARN messager/métabolismeRÉSUMÉ
The effects of exogenous and endogenous cannabinoids on the cardiovascular system have been the focus of extensive research. The direct and indirect effects of cannabinoids on heart and blood vessels depend upon experimental conditions, animal species, and, in humans, clinical background. Cannabinoids decrease blood pressure in hypertensive rodents primarily because of decrease cardiac contractility, leading researchers to postulate a role in the treatment of hypertension and cardiac hypertrophy. Rimonabant, the CB(1) receptor blocker in clinical use in many countries, induced a marked and sustained increase in cardiac contractility and blood pressure in hypertensive rats but, on the contrary, contributed to decrease blood pressure in weight-loss clinical trials especially in obese patients with hypertension. In the midst of the obesity pandemic and from the cardiometabolic point of view, the overactivation of the endocannabinoid system present in intra-abdominal obesity appears to be very harmful. Moreover, novel human findings suggest a relationship between CB(1)-mediated overactive endocannabinoid system and nephrovascular damage. Overall, it appears that CB(1) blockade in obese patients behaves as a 'multiplier' of the many beneficial effects of body weight loss induced by a hypocaloric diet and increased physical activity (the 'lifestyle changes' that are so difficult to start and maintain). Thus, the concept - based mostly on experimental results using in vitro or animal models - that CB(1)-mediated endocannabinoid effects are beneficial for the cardiovascular system should be revised at least in obese patients. The results of long-term clinical trials such as the STRADIVARIUS and the CRESCENDO trials will tell whether the improvement in the cardiometabolic risk profile induced by Rimonabant translates into vascular changes, reducing the risk of myocardial infarction, stroke and cardiovascular death in patients with abdominal obesity. Time (and much more work) will tell us much more about cannabinoids and the human heart.
Sujet(s)
Pression sanguine/physiologie , Modulateurs des récepteurs de cannabinoïdes/physiologie , Endocannabinoïdes , Coeur/physiologie , Vaisseaux sanguins/physiologie , Cannabinoïdes/usage thérapeutique , Phénomènes physiologiques cardiovasculaires , Système cardiovasculaire/physiopathologie , Essais cliniques comme sujet , Humains , Obésité/complications , Obésité/traitement médicamenteux , Obésité/physiopathologie , Pipéridines/usage thérapeutique , Pyrazoles/usage thérapeutique , RimonabantSujet(s)
Hypertension artérielle/génétique , Syndrome métabolique X/génétique , Obésité/génétique , Facteurs de transcription TCF/génétique , Adulte , Allèles , Analyse de variance , Loi du khi-deux , Femelle , Prédisposition génétique à une maladie , Génotype , Humains , Mâle , Adulte d'âge moyen , Phénotype , Facteurs de risqueRÉSUMÉ
OBJECTIVE: Cardiovascular peptides such as angiotensin II (Ang II) and atrial natriuretic peptide (ANP) have metabolic effects on adipose cells. These peptides might also regulate adipocyte proliferation and visceral adipose tissue (VAT) expansion. Well-differentiated and stabilized primary cultures of human visceral mature adipocytes (MA) and in vitro-differentiated preadipocytes (DPA) were used as a model to study regulation of VAT expansion. METHODS: Adipocyte differentiation was evaluated by Oil Red O staining and antiperilipin antibodies. MA and DPA from intra- and retro-peritoneal depots were treated with increasing Ang II (with or without valsartan, a highly selective, competitive, 'surmountable' AT1 antagonist devoid of peroxisome proliferator-activated receptor gamma agonistic activity) or ANP concentrations. Cell counts and bromodeoxyuridine incorporation were used to evaluate proliferation. Apoptosis was evaluated by Hoechst 33342 staining. 8-Bromo cyclic guanosine monophosphate (8Br-cGMP) was used to investigate ANP effects, and real-time PCR to evaluate Ang II and ANP receptors' expression. RESULTS: Cell proliferation was progressively stimulated by increasing Ang II concentrations (starting at 10-11 M) and inhibited by ANP (already at 10-13 M) in both MA and DPA. Co-incubation with increasing Ang II concentrations and valsartan indicated that Ang II effects were AT1-mediated. Indeed, AT2 receptors were not expressed. Valsartan alone slightly inhibited basal proliferation indicating an autocrine/paracrine growth factor-like effect of endogenous, adipocyte-derived Ang II. 8Br-cGMP experiments indicated that the effects of ANP were mediated by the guanylyl cyclase type A receptor. CONCLUSION: A cell-culture model to study VAT growth showed stimulation by Ang II and inhibition by ANP at physiological concentrations. Because similar effects are likely to occur in vivo, Ang II and ANP might be important modulators of VAT expansion and associated metabolic and cardiovascular consequences.
Sujet(s)
Adipocytes/effets des médicaments et des substances chimiques , Tissu adipeux/effets des médicaments et des substances chimiques , Angiotensine-II/pharmacologie , Facteur atrial natriurétique/pharmacologie , Graisse intra-abdominale/effets des médicaments et des substances chimiques , Adipocytes/cytologie , Tissu adipeux/cytologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Différenciation cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Femelle , Humains , Graisse intra-abdominale/cytologie , Mâle , Adulte d'âge moyenRÉSUMÉ
Increased aldosterone secretion has been found in a mouse lacking the KCNE1 gene which codes for a regulatory protein of the KCNQ1 gene product, forming the channel for the outward rectifying delayed K+ current. Abnormalities in proteins regulating the K+ fluxes across membranes may be responsible for aldosterone-secreting adenomas (aldosteronomas) also because K+ channels are involved in cell growth. Normal and adenomatous adrenal samples and NCI-H295 cell line were used to: a) evaluate KCNE1 and KCNQ1 gene expression, b) sequence the full length cDNAs of KCNE1 and both KCNQ1 isoforms. These differently spliced KCNE1 and KCNQ1 mRNAs were expressed in adrenal tissue. In contrast, KCNQ1 isoform 2 mRNA was not expressed in kidney control tissues and NCl-H295 cell line. NCI-H295 cell line also had a significantly lower expression of KCNQ1 isoform 1 mRNA than normal adrenals and aldosteronomas. We did not find any somatic mutations in the coding sequences of both genes. This different expression pattern of KCNQ1 isoforms in NCI-H295 cell line with the lack of the mRNA for the dominant-negative KCNQ1 isoform 2 supports the involvement of voltage-gated K+ channel in cell proliferation.
Sujet(s)
Adénomes/métabolisme , Glandes surrénales/métabolisme , Canal potassique KCNQ1/métabolisme , Canaux potassiques voltage-dépendants/métabolisme , Adulte , Sujet âgé , Aldostérone/métabolisme , Études cas-témoins , Lignée cellulaire tumorale , Femelle , Humains , Canal potassique KCNQ1/génétique , Rein/métabolisme , Mâle , Adulte d'âge moyen , Mutation , Canaux potassiques voltage-dépendants/génétique , Analyse de séquence d'ADNRÉSUMÉ
Erectile dysfunction (ED) is frequent in patients with essential hypertension (EH); a likely common pathogenetic pathway could be a reduced ability of arteriolar vascular smooth muscle (VSM) to relax. Increasing intracellular levels of cGMP reduce the contractile status of VSM; on the contrary, type 5 cGMP-specific phosphodiesterase (PDE5, codified by PDE5A gene) regulates cGMP levels through its clearance. The PDE5A gene represents a good candidate for the intermediate phenotype EH/ED: genetic variants of the PDE5A may predispose to EH and ED and could affect the local and systemic response to sildenafil administration. Thus, a functionally relevant portion of PDE5 5'-flanking promoter region was analyzed by PCR and direct sequencing in patients with EH and idiopathic ED. The sequences obtained showed a T/G polymorphism at position -1142, near an AP1 regulatory element, that was not apparently associated with the intermediate phenotype. We also studied the relationship between this polymorphism and the effects of oral sildenafil on blood pressure (BP) and heart rate (HR) in men with ED. Sildenafil caused a significant decrease of BP, but had no effects on HR; statistical analysis showed no differences in BP and HR variations among PDE5A genotypes. In conclusion, our data showed no correlations of a novel polymorphism of the PDE5A promoter gene with the intermediate phenotype EH/ED and the BP and HR response to sildenafil administration. Further studies are necessary to define the role of this polymorphism and to study the genetic predisposition for EH with ED.
Sujet(s)
3',5'-Cyclic-GMP Phosphodiesterases/biosynthèse , 3',5'-Cyclic-GMP Phosphodiesterases/génétique , Dysfonctionnement érectile/génétique , Dysfonctionnement érectile/physiopathologie , Hémodynamique/effets des médicaments et des substances chimiques , Hypertension artérielle/génétique , Hypertension artérielle/physiopathologie , Pipérazines/pharmacologie , Vasodilatateurs/pharmacologie , Région 5' flanquante/génétique , Adulte , Sujet âgé , Allèles , Cyclic Nucleotide Phosphodiesterases, Type 5 , ADN/génétique , Dysfonctionnement érectile/complications , Génotype , Humains , Hypertension artérielle/complications , Mâle , Adulte d'âge moyen , Purines , RT-PCR , Citrate de sildénafil , Sulfones , Facteur de transcription AP-1/génétiqueRÉSUMÉ
AIM: There is recent evidence that the natriuretic peptide (NP) system promotes adipose tissue lipolysis in primates. This effect is mediated by the interaction of NP with its active receptors through guanylyl cyclase activation and cGMP production. This review will briefly focus on the new aspects of NP pathophysiology in man. DATA SYNTHESIS: NP receptors have been described in rodent adipocytes, and the expression of their mRNA is found in human adipose tissue together with high level of ANP binding sites. In isolated fat cells, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were able to stimulate lipolysis as much as isoproterenol, a non-selective beta-adrenergic receptor agonist, whereas C-type natriuretic peptide (CNP) had the lowest lipolytic effect. The potent lipolytic effect of NP has also been confirmed in samples of abdominal adipose tissue from healthy subjects. The potency order of the lipolytic effect (ANP > BNP > CNP) and ANP-induced cGMP production supported the presence of type A natriuretic peptide receptor in human fat cells. The effect of NP on lipid metabolism is confirmed by the fact that intravenous ANP infusion is followed by plasma NEFA and glycerol concentration increase (reflecting lipid mobilisation). CONCLUSIONS: The NP system seems to play an important role in lipid metabolism, possibly affecting the pathophysiology of obesity and obesity-related disorders, such hypertension. Further studies, however, are needed to completely establish the mechanisms involved in NP-induced lipolysis and the real relevance of this new pathway specific of primates.
Sujet(s)
Lipolyse , Peptides natriurétiques/métabolisme , Obésité/physiopathologie , HumainsRÉSUMÉ
Somatic mutations of genes codifying for key regulatory proteins are the cause of different types of hormone-secreting adenomas. Natriuretic peptides (NP) are the strongest inhibitors of aldosterone secretion but aldosterone-secreting adenomas (aldosteronomas) are resistant to this inhibition and have reduced binding sites for NPs. The objective of this study was to sequence the entire coding region of the NP receptor type A (NPRA, codified by the Npr1 gene) to find loss-of-function somatic mutations. Total RNA was extracted from eight aldosteronomas and cDNA was synthesized. NPRA mRNA expression was evaluated by Northern blot analysis and compared with beta-actin mRNA as the housekeeping gene. Twelve primer couples were designed on the basis of the Npr1 gene organization to amplify, by PCR, all 22 coding exons of the gene. The two strands of amplified DNAs were purified and directly sequenced by automated capillary sequencer. NPRA mRNA expression did not differ among aldosteronomas. Npr1 open reading frame sequences obtained from eight aldosteronomas did not contain any mutation. The coding sequences of all 22 exons were identical in all samples and identical to published sequences. In the 3'-untranslated region (3'-UTR) a new length difference 3C/4C polymorphism was found at position 15 129 (three adenomas were 3C/4C and two were 3C/3C). Such a 3C/4C polymorphism was present in genomic DNA from 80 control subjects (25, 4C/4C; 40, 3C/4C; 15, 3C/3C). Mutations in the coding exons of the Npr1 gene do not appear to be a common cause of aldosteronomas. Moreover, the exons of Npr1 encoding for the translated portion of mRNA do not appear to be prone to polymorphisms. The polymorphism identified in the 3'-UTR might affect mRNA stability resulting in lower receptor synthesis, but it is not likely to confer a predisposition to the development of aldosteronomas.
Sujet(s)
Adénomes/métabolisme , Tumeurs de la surrénale/métabolisme , Guanylate cyclase/génétique , Mutation , Récepteur facteur natriurétique auriculaire/génétique , Adénomes/génétique , Adénomes/anatomopathologie , Tumeurs de la surrénale/génétique , Tumeurs de la surrénale/anatomopathologie , Glandes surrénales/métabolisme , Glandes surrénales/anatomopathologie , Aldostérone/génétique , Aldostérone/métabolisme , Technique de Northern , Femelle , Humains , Mâle , Réaction de polymérisation en chaîne , ARN messager/métabolisme , Analyse de séquence d'ADNRÉSUMÉ
A 43-year-old Albanian man is presented who underwent nephrectomy for a huge right spontaneous perirenal hematoma. The diagnosis of polyarteritis nodosa as the etiology of the hematoma has been made only by histological examination, because of the quick and unforeseeable onset of this complication and the nonspecificity of symptoms. We hypothesize a relationship between reactivation of polyarteritis nodosa and treatment with rifampicin and isoniazid.
Sujet(s)
Hématome/étiologie , Hypertension rénale/étiologie , Maladies du rein/étiologie , Polyartérite noueuse/complications , Adulte , Antituberculeux/usage thérapeutique , Humains , Isoniazide/usage thérapeutique , Rein/anatomopathologie , Mâle , Infections à mycobactéries non tuberculeuses/traitement médicamenteux , Néphrectomie , Rifampicine/usage thérapeutiqueRÉSUMÉ
The C(-344)T promoter polymorphism of the human aldosterone synthase (CYP11B2) gene has been associated with hypertension and cardiac hypertrophy, but there were contrasting data. We analysed the genotype/phenotype associations between this polymorphism and cardiovascular variables in a young adult population, where interactions among genes, gene-environment, and acquired ageing-related organ damage are reduced. Anthropometric measurements, blood pressure, heart rate, left ventricular variables (by echocardiography), and carotid artery wall intimal-media thickness (by high-resolution sonography and digitalized morphometry) were taken in 420 white Caucasian students (mean age 23.5 years, s.d. 2.5 years). CYP11B2 alleles were detected by genomic polymerase chain reaction followed by digestion. Taking into account the three possible models of inheritance, we found no differences in the considered variables, except for an independent effect of the C(-344) allele on SBP in males (TT 125.6 (1.6), TC 128.4 (1.2) and CC 130.5 (2.2), mmHg, media (ES), P=0.03), and on interventricular septum thickness in diastole in females (CC 6.98 (0.12) vs TT 6.87 (0.09) and TC 6.87 (0.07), mmHg, P<0.01), in the codominant model. In conclusion, the CYP11B2 C(-344)T polymorphism appears to have a slight role in the cardiovascular phenotype of young healthy adults, even if these genotype/phenotype relationships might change with ageing.
Sujet(s)
Allèles , Maladies cardiovasculaires/génétique , Cytochrome P-450 CYP11B2/génétique , Adulte , Analyse de variance , Anthropométrie , Pression sanguine , Loi du khi-deux , Femelle , Variation génétique , Génotype , Humains , Mâle , Phénotype , Réaction de polymérisation en chaîneRÉSUMÉ
OBJECTIVES AND DESIGN: Angiotensinogen (AGT) gene variants influence angiotensinogen plasma levels in children and young adults. The angiotensinogen promoter (-6)A variant facilitates gene transcription in human tissues and it has been associated with high blood pressure in older adults. A young adult population can be used as a model to study genotype/phenotype associations between AGT (-6) variants and cardiovascular variables. METHODS AND RESULTS: Anthropometric measurements, blood pressure and heart rate were taken in 422 white Caucasian students (mean age 23.5 years, SD 2.5 years). Family history for hypertension, physical activity and smoking history were evaluated. Left ventricular variables were measured by echocardiography. Carotid artery wall intimal-media thickness (IMT) was measured by high resolution sonography and digitalized morphometry. The AGT G(-6)A alleles were evaluated by mutagenically separated polymerase chain reaction controlled by direct sequencing. No significant associations were found between angiotensinogen genotype and blood pressure, cardiac variables [except for deceleration time in females which increased with the number of (-6)A alleles] and IMT. Allele frequencies were similar between the first and third tertile of blood pressure and left ventricular mass, and were also similar between negative or positive family history for hypertension (the last group having significantly higher systolic blood pressure in males, P = 0.04 and diastolic blood pressure in females, P < 0.01). Moreover, no relevant interaction on the cardiovascular variables was found between AGT genotype and body mass index. CONCLUSIONS: The angiotensinogen G(-6)A variants do not affect cardiovascular parameters in young adults, but an effect of this polymorphism on cardiovascular phenotype (and hypertension) in older adults cannot be excluded. Additional factors, associated with ageing, should be present to unleash the supposed unfavourable potential of the (-6)A angiotensinogen variant.
Sujet(s)
Allèles , Angiotensinogène/génétique , Phénomènes physiologiques cardiovasculaires , Adulte , Pression sanguine , Artères carotides/imagerie diagnostique , Échocardiographie , Variation génétique , Génotype , Humains , Phénotype , Tunique intime/imagerie diagnostique , Tunique moyenne/ultrastructureRÉSUMÉ
Leptin is a circulating hormone which plays an important role in the regulation of energy balance, haemopoiesis and reproduction. Leptin and its receptor (leptin-R) are localized in human placental tissue but their function is not known. In this study we have investigated the expression of leptin and leptin-R in the human placenta with particular attention to extravillous cytotrophoblastic cell islands and cell columns which play a pivotal role in trophoblast invasion and placental growth. We demonstrate that leptin-R immunoreactivity shows a strong expression in the distal extravillous cytotrophoblastic cells of cell columns invading the basal plate, whereas leptin expression is homogeneously expressed in all the cellular components of cell columns. Since the invasive ability of the distally located extravillous cytotrophoblast of cell columns is known to be regulated by a variety of proteases and some extracellular matrix molecules, we tested the influence of leptin on the in-vitro production of matrix metalloproteinase (MMP)-2, MMP-9 and fetal fibronectin (fFN) by cytotrophoblastic cells. We demonstrate that leptin increases, in a dose-dependent manner, the secretion of immunoreactive MMP-2 and fFN and enhances the activity of MMP-9 in cultured cytotrophoblastic cells. Our results suggest that leptin and leptin-R could have a role in the invasive processes of the extravillous cytotrophoblastic cells by modulating the expression of MMPs. In addition, these results provide a foundation for studying pathological conditions characterized by insufficient or excessive trophoblast invasion.
Sujet(s)
Protéines foetales/métabolisme , Fibronectines/métabolisme , Leptine/métabolisme , Matrix metalloproteinase 2/métabolisme , Matrix metalloproteinase 9/métabolisme , Récepteurs de surface cellulaire , Trophoblastes/physiologie , Protéines de transport/génétique , Protéines de transport/métabolisme , Cellules cultivées , Villosités choriales/métabolisme , Test ELISA , Femelle , Humains , Kératines/analyse , Leptine/génétique , Leptine/immunologie , Leptine/pharmacologie , Matrix metalloproteinase 9/isolement et purification , Placenta/cytologie , Grossesse , Premier trimestre de grossesse , Troisième trimestre de grossesse , Récepteurs à la leptine , Protéines recombinantes/pharmacologie , Trophoblastes/effets des médicaments et des substances chimiquesRÉSUMÉ
OBJECTIVE AND DESIGN: The clearance receptor for natriuretic peptides (NPRC), a candidate gene for essential hypertension, is highly expressed in adipose tissue, where is nutritionally regulated. The objectives of the present study were to sequence the human 5'-flanking regulatory region of NPRC, to identify allelic variants and their frequencies, and to study the genotype/phenotype correlation in hypertensive patients. METHODS AND RESULTS: Using polymerase chain reaction (PCR) and direct automated sequencing, a biallelic (A/C) polymorphism was detected at position -55 in a conserved promoter element named P1. The novel C(-55) variant makes the promoter sequence identical to the mouse gene and introduces a second Hgal site in the amplified DNA, allowing the genotyping of a large number of subjects. In a random sample of 232 white Caucasians the C(-55) allele was more commonly found (81.7% of all alleles) with 155 CC (66.8%), 69 AC (29.7%) and only eight AA (3.5%) genotypes. Atrial natriuretic peptide (ANP) levels were determined in 84 patients with essential hypertension. In the presence of obesity (body mass index (BMI) > or = 30 kg/m2) the homozygous CC hypertensives (n = 21) had significantly lower plasma ANP (33.6 +/- 11.1 pg/ml) compared with the AC patients (n = 11; 46.8 +/- 15.9 pg/ml; P = 0.01), whereas systolic blood pressure (SBP) and mean blood pressure (MBP) had the opposite association (SBP 163.9 +/- 18.7 versus 150.9 +/- 12.9 and MBP 123.3 +/- 12 versus 114.5 +/- 5.9 mmHg; P< 0.05). The difference in ANP levels were also present when overweight patients (BMI > or = 27 kg/m2) were considered. CONCLUSION: A common 'ancestral' C(-55) variant of the NPRC P1 promoter is associated with lower ANP levels and higher SBP and MBP in obese hypertensives. The C(-55) variant, in the presence of increased adiposity, might reduce plasma ANP through increased NPRC-mediated ANP clearance, contributing to higher blood pressure.
Sujet(s)
Facteur atrial natriurétique/sang , Pression sanguine/génétique , Guanylate cyclase/génétique , Hypertension artérielle/génétique , Obésité/génétique , Obésité/physiopathologie , Récepteur facteur natriurétique auriculaire/génétique , Adulte , Sujet âgé , Allèles , Animaux , Indice de masse corporelle , Femelle , Fréquence d'allèle , Dépistage génétique , Génotype , Humains , Hypertension artérielle/sang , Mâle , Souris , Adulte d'âge moyen , Données de séquences moléculaires , Réaction de polymérisation en chaîne , Polymorphisme génétique/génétique , Régions promotrices (génétique)/génétique , Séquences d'acides nucléiques régulatrices/génétique , Similitude de séquences d'acides nucléiquesRÉSUMÉ
Atrial natriuretic peptide (ANP) and B-type or brain natriuretic peptide (BNP) inhibit aldosterone secretion in humans both in vitro and in vivo. Unresponsiveness of aldosterone-secreting adenomas (aldosteronomas) to ANP in vitro and in vivo, might be due to reduced expression of the biologically-active natriuretic peptide receptor type A (NPr-A) and/or increased expression of the clearance receptor for natriuretic peptides (NPr-C). Therefore, we have analyzed NPr gene expression and ANP binding sites in human adrenals and aldosteronomas. Using reverse transcription and polymerase chain reaction, we cloned and characterized cDNAs for NPr-A, NPr-C, and the receptor (NPr-B) for the C-type natriuretic peptide (CNP). Total RNA from three normal human adrenals (obtained at surgery from patients with renal cancer) and five aldosteronomas were used for Northern analysis. NPr-A mRNA (approximately 4 kb) and NPr-B mRNA (approximately 4 kb) were expressed without significant differences in adrenals and in aldosteronomas except in an aldosteronomas that contained only very low amounts of NPr mRNAs. The gene expression of NPr-C was barely detectable both in adrenals and in aldosteronomas. ANP binding sites were analyzed by autoradiography with 125I-labeled ligand in other six aldosteronomas. Only one of the adenomas analyzed showed ANP binding sites with density of granules similar to nonadenomatous glomerulosa, whereas the others had significantly reduced densities. In summary, aldosteronomas express the genes encoding for NPr but mainly NPr-A, similarly to control adrenals. On the contrary, the binding sites for ANP are greatly reduced in most aldosteronomas. A somatic mutation or a post-transcriptional defect that reduces ANP binding sites might be present in some aldosteronomas.
Sujet(s)
Adénomes/métabolisme , Tumeurs de la surrénale/métabolisme , Aldostérone/métabolisme , Guanylate cyclase/génétique , Récepteur facteur natriurétique auriculaire/génétique , Adénomes/composition chimique , Tumeurs de la surrénale/composition chimique , Glandes surrénales/composition chimique , Glandes surrénales/métabolisme , Facteur atrial natriurétique/métabolisme , Autoradiographie , Technique de Northern , Expression des gènes , Guanylate cyclase/métabolisme , Humains , ARN messager/analyse , Récepteur facteur natriurétique auriculaire/métabolisme , RT-PCRRÉSUMÉ
The expression of the natriuretic peptide clearance receptor is abundant in human and rat adipose tissue, where it is specifically inhibited by fasting. In obese hypertensives, plasma atrial natriuretic peptide (ANP) levels were found to be lower than in obese normotensives. Therefore, the increased adipose mass might influence ANP levels and/or its biological activity. The aim of the present study was to evaluate whether the humoral, hemodynamic, and renal effects of exogenous ANP in obese hypertensives might be enhanced by a very low calorie diet. Eight obese hypertensives received a bolus injection of ANP (0.6 mg/kg) after 2 weeks of a normal calorie/normal sodium diet, and blood pressure (BP), heart rate, ANP, cGMP, plasma renin activity, and aldosterone were evaluated for 2 hours before and after the injection. Diuresis and natriuresis were measured every 30 minutes. The patients then started a low calorie/normal sodium diet (510 kcal/150 mmol/d) for 4 days, and then the ANP injection protocol was repeated. The low calorie diet induced a slight weight loss (from 90.6+/-1.1 to 87. 7+/-1.2 kg; P<0.01), which was accompanied by increase of cGMP excretion (from 146.0+/-10.1 to 154.5+/-9.5 nmol/24 h; P<0.05) together with a reduction of BP (P<0.01 versus basal levels). ANP injection after diet was followed by an increase of ANP levels similar to that observed before diet, but plasma cGMP, diuresis, and natriuresis increased significantly only after diet. Similarly, the decrease of BP after ANP administration was significantly higher after diet (change in mean arterial pressure, -6.4+/-0.7 versus -4. 0+/-0.6 mm Hg; P<0.05) as well as that of aldosterone (P<0.01). These data show that a low calorie diet enhances the humoral, renal, and hemodynamic effects of ANP in obese hypertensives and confirm the importance of caloric intake in modulating the biological activity of ANP, suggesting that the natriuretic peptide system can play a role in the acute changes of natriuresis and diuresis associated with caloric restriction.
Sujet(s)
Facteur atrial natriurétique/administration et posologie , Régime alimentaire , Diurèse/effets des médicaments et des substances chimiques , Hémodynamique/effets des médicaments et des substances chimiques , Hypertension artérielle/traitement médicamenteux , Hypertension artérielle/physiopathologie , Obésité/traitement médicamenteux , Obésité/physiopathologie , Aldostérone/sang , Animaux , Femelle , Humains , Hypertension artérielle/sang , Hypertension artérielle/complications , Mâle , Adulte d'âge moyen , Obésité/sang , Obésité/complications , Rats , Rénine/sangRÉSUMÉ
In a previous work we showed that only unilocular brown adipocytes express leptin. In order to investigate the relationship between leptin gene expression, brown adipocyte activity (UCP1) and morphology, we studied brown adipose tissues of mice (C57BL, female, 7 weeks old) acclimated at different temperatures (19 degrees C and 28 degrees C). Northern blot analysis revealed higher leptin and lower UCP1 mRNA levels in mice exposed to 28 degrees C than in the group acclimated at 19 degrees C. Also protein expression (immunohistochemistry) differed in the two groups: at 28 degrees C brown adipocytes were positive for leptin and only weakly positive for UCP1, while at 19 degrees C they were leptin-negative and UCP1-positive. In the former group the morphology was mainly unilocular. Our data suggest that in brown adipocytes of warm-acclimated mice leptin expression is closely related to their hypoactive functional stage, as evidenced by their low level of UCP1 synthesis and the morphological rearrangement of the lipid content (unilocularity).